Global Hypoxia Treatment Market - 2023-2030

Market Overview

Global Hypoxia Treatment Market reached US$ 77.6 million in 2022 and is expected to reach US$ 134.3 million by 2030 growing with a CAGR of 7.2% during the forecast period 2023-2030. Factors such as the increasing prevalence of hypoxia conditions, continuous advancements in technology, rising clinical trials, increasing consumer demand, and growing FDA approvals are likely to boost the hypoxia treatment market.

Hypoxia is linked to several biological processes which include pathogenic microbe infection, cancers, acute and chronic diseases, and many other stress responses. Hypoxia-inducible factors (HIFs) sense hypoxia to regulate the expressions of a series of downstream genes expression, which participate in multiple processes including cell metabolism, cell death, cell proliferation, glycolysis, immune response, microbe infection, and metastasis.

Market Dynamics

Rising Technological Advancements in Hypoxia Treatment are Expected to Boost the Global Market Growth

The hypoxia treatment market has witnessed significant growth due to various technological advancements. Many key players play a major role in these advancements by launching new products and services. This new product or service can rise the productivity and efficacy of the diagnostic or medical device.

For instance, on June 20, 2023, Akebia Therapeutics, Inc. announced that the Swiss agency for therapeutic products granted marketing authorization for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

The Swissmedic approval of Vafseo is based on data from a development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Rising FDA Approvals for Hypoxia Conditions are Expected to Boost the Global Hypoxia Treatment Market

The increasing FDA approvals for hypoxia conditions such as asthma, COPD, and pneumonia act as a major driver for the market growth. Also, many key players play a major role in the advancements of the market by launching new products and services.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

Additionally, on March 15, 2022, the U.S. Food and Drug Administration (FDA) approved the first generic of Symbicort Inhalation Aerosol for the treatment of two common pulmonary health conditions that is asthma in patients six years of age and older and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis. This complex generic drug-device combination product, are not used to treat acute asthma attacks. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Lack of Awareness Associated with Hypoxia Conditions such as COPD is Expected to Hamper Global Hypoxia Treatment Market Growth

According to Dove Press, epidemiological studies were conducted to access the prevalence of COPD in the Aseer region of Saudi Arabia. The awareness regarding the COPD condition was low among the people of the region. Only 34.0% correctly knew that quitting smoking has an important role in preventing COPD. This study needs an urgent need of improving awareness of COPD and its risk factors in the general population. This subject should be strengthened in the curriculum and discussed in public campaigns and seminars. Furthermore, nationwide study is required to help the policymakers for implementing suitable preventive and curative strategies to promote the pulmonary health of the population.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the hypoxia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of hypoxia conditions and initiation of treatment for patients. As a result, some hypoxia disease cases were diagnosed at later stages, potentially affecting treatment outcomes.

Clinical trials are vital for developing new treatments and improving outcomes in the hypoxia treatment market. However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of hypoxia related research and development activities.

Also, to minimize the risk of COVID-19 transmission, healthcare providers implemented changes in treatment delivery, such as reducing in-person clinic visits, increasing telemedicine consultations, and modifying treatment schedules. These changes have impacted the overall patient experience and the management of the hypoxia treatment market.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of hypoxic diseases such as asthma and COPD. The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, may be damaged or inaccessible, making it challenging for patients with hypoxic diseases to receive proper diagnosis, treatment, and follow-up care.

The conflict can result in limited availability of medical resources, including medical devices, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for hypoxic disorders patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their chronic pain disorder treatment.

Furthermore, the conflict and its aftermath may hinder data collection and research efforts related to hypoxic diseases in the affected regions. This can impact the availability of up-to-date epidemiological data, hinder clinical trials, and limit the understanding of hypoxic treatment outcomes in conflict-affected areas. Therefore, considering the above factors, the hypoxic treatment market has been moderately affected by the conflict between Russia and Ukraine.

Segment Analysis

The global hypoxia treatment market is segmented based on type, disease type, end users, and region.

Owing to Rising Clinical Trials, the Hypoxic Hypoxia Segment Accounted for Approximately 48.6% of the Hypoxia Treatment Market Share

According to ClinicalTrials.gov, on April 25, 2023, Capital Medical University conducted a clinical trial on an exploratory study of intermittent hypoxia treatment in chronic cerebral hypoperfusion. This interventional study aims to investigate the safety and efficacy of intermittent hypoxia treatment in patients with chronic cerebral hypoperfusion. This study is an exploratory study combining intermittent hypoxia treatment with chronic cerebral hypoperfusion, aiming to preliminarily explore the safety and potential effectiveness of intermittent hypoxia treatment in the use of chronic cerebral hypoperfusion. The estimated study completion date is Oct 10, 2023.

Additionally, On Feb 1, 2023, GSK announced that Jesduvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has received the US Food and Drug Administration (FDA), for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for four months. Jesduvroq is the first innovative medicine for anemia treatment in over 30 years and the only HIF-PHI approved in the US, providing a new oral and convenient option for patients in the US with anemia of CKD on dialysis. Thus, owing to the above factors, the CMOS segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share in 2022, Owing to the Increasing Research and Development Activities and Well-Established Healthcare Infrastructure

The North American region is anticipated to experience growth in the field of hypoxia treatments due to factors such as rising research and development efforts, a robust healthcare infrastructure, and supportive reimbursement systems. These factors contribute to increased accessibility for patients to access advanced therapies, facilitating the adoption of cutting-edge treatments. This trend is expected to drive the North American region's progress in hypoxia treatment throughout the forecast period.

For instance, on Aug 13, 2021, Merck & Co. announced that WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor received FDA approval for the treatment of adult patients with Von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

WELIREG is the first HIF-2α inhibitor therapy approved in the U.S. As an inhibitor of HIF-2α, WELIREG reduces transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis, and tumor growth.

Competitive Landscape

The major global players in the market include: CASI Pharmaceuticals Inc., Aileron Therapeutics, Inc., Lupin Pharmaceuticals, Inc., PharmaShots, Hancock Medical Inc., Hamilton Company, Spotlight Labs, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., and Merck & Co among others.

Why Purchase the Report?

• To visualize the global hypoxia treatment market segmentation based on the type, disease type, end users, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hypoxia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hypoxia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies